RGEN — REPLIGEN CORP

Nasdaq · Health Care · Biotechnology · CIK 730272 ·
Last close
$141.01
Market Cap
$7.96B
52W High
$154.00
52W Low
$100.99
ADV30
1,253,797
Next earnings
2026-07-28
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026 204,128,000 110,037,000 19,002,000 5,008,000 2,950,180,000 606,783,000 838,148,000
Mar 2026
Dec 2025 197,913,000 103,831,000 16,348,000 13,287,000 2,949,699,000 566,021,000 843,570,000
Sep 2025 188,805,000 100,515,000 12,677,000 14,911,000 2,923,711,000 748,747,000 840,624,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$117,417,000
Investing CF
$-298,474,000
Financing CF
$-15,205,000
CapEx
$-25,730,000
Dividends Paid
Buybacks
EPS Diluted TTM
$0.90
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$456,248,000
Inventory
$170,458,000
Receivables
$158,587,000
ST Investments
$201,607,000
EBIT TTM
$70,703,000
Pretax Income TTM
$54,440,000
Interest Exp TTM
$16,263,000
Analysts
18

Yahoo Snapshot (yfinance, live)

Total Revenue
$785,100,992
EBITDA
$144,100,992
Free Cash Flow
$113,421,752
Enterprise Value
$7,984,648,192
Total Cash
$810,449,024
Total Debt
$690,942,016
Shares Out
56,435,621
Trailing EPS
$0.73
Book Value
$37.33
ROE
2.0%
ROA
1.4%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 738,256,000 41,560,000 48,894,000 2,949,699,000 843,570,000 117,417,000
Dec 2024 634,439,000 -31,923,000 -25,514,000 2,829,666,000 856,948,000 175,394,000
Dec 2023 632,362,000 17,134,000 35,596,000 2,831,185,000 866,340,000 113,918,000
Dec 2022 801,536,000 195,941,000 185,959,000 2,531,600,000 620,900,000 172,083,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$2.64

Max Pain — expiry 2026-11-20

max pain strike: $135.00 · spot: $141.01 · call oi: 388 · put oi: 2,975
Expected Move to 2026-11-20: ±$32.30 (22.91%) — implied range $108.71$173.31 · ATM straddle on $140.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
IMVT Immunovant, Inc. $7.93B $38.62
PCVX Vaxcyte, Inc. $7.81B $54.08
APGE Apogee Therapeutics, Inc. $8.27B $134.09
IBRX ImmunityBio, Inc. $7.51B $7.17
KYMR Kymera Therapeutics, Inc. $8.51B $103.40

News headlines (Yahoo Finance, 1h cache)

AMRX Down Despite Q2 Earnings Beat, 2026 Revenue Outlook Raised
2026-07-31 15:14 · Yahoo
Wall Street Analysts Believe Repligen (RGEN) Could Rally 25.72%: Here's is How to Trade
2026-07-30 13:55 · Yahoo
Repligen Beats Q2 Earnings Estimates, Raises 2026 View, Stock Up
2026-07-29 16:23 · Yahoo
Why Repligen (RGEN) Stock Is Up Today
2026-07-29 08:21 · Yahoo
Repligen (RGEN) Held An M&A Call With BioLife Solutions.
2026-07-28 20:12 · Yahoo
Repligen Corp (RGEN) Q2 2026 Earnings Call Highlights: Strong Growth and Raised Guidance Amidst ...
2026-07-28 19:01 · Yahoo
Repligen Q2 Earnings Call Highlights
2026-07-28 15:04 · Yahoo
Repligen Reports Q2 Revenue Growth and Raises Full-Year 2026 Guidance
2026-07-28 14:05 · Yahoo
Repligen (RGEN) Beats Q2 Earnings and Revenue Estimates
2026-07-28 12:15 · Yahoo
Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q2 CY2026
2026-07-28 11:22 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.